Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 is involved in cognitive brain function and learning, 98”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [98]
In the citing paper
“GLP1-RAs is known for its neuroprotective action, and more recent results have emerged, showing a potential benefit in people with AD [85,86,87].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [86]
In the citing paper
“They are involved in multiple biological pathways that could be beneficial in AD including improvement of BBB integrity and vascular health, promotion of homeostasis in microglia and astrocytes, positive effects on adaptative immune cells (including natural killer cells and activated regulatory T cells), improvement of synaptic viability, and neuroprotection [17–26].”
In the citing paper
“Preclinical results in murine models treated with GLP-1RAs suggest that the potential effects of semaglutide in AD may be exerted via impact on several AD-related pathophysiologic processes including neuroinflammatory pathways, vascular and BBB integrity, reduced synaptic loss, and neuroprotection [19, 21, 23–26, 46–48];”
Citations
Cites
Modification of seizure activity by electrical stimulation: II. Motor seizure
Racine, R. J. (1972) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(72)90177-0 · Cited by 7,171
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
The molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218 · cited 1×
“Immunohistochemical comparison of the CA3 subregion of the hippocampus using Fluorojade-B, a fluorochrome stain specific for degenerating neuron”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationEnvironmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective
Young, D., Lawlor, P. A., Leone, P., Dragunow, M., & During, M. J. (1999) · Nature Medicine · doi:10.1038/7449 · Cited by 732
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citation
Cited by
Items 101–200 of 859
Nose-to-brain peptide delivery – The potential of nanotechnology
Samaridou, E., & Alonso, M. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.001 · Cited by 178
Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 169
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Werner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
The benefits of GLP-1 drugs beyond obesity
Drucker, D. J. (2024) · Science · doi:10.1126/science.adn4128 · Cited by 165
Self-citationMansur, R. B., Ahmed, J., Cha, D. S., Woldeyohannes, H. O., Subramaniapillai, M., Lovshin, J., Lee, J. G., Lee, J.-H., Brietzke, E., Reininghaus, E. Z., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.056 · Cited by 164
Luo, A., Xie, Z., Wang, Y., Wang, X., Li, S., Yan, J., Zhan, G., Zhou, Z., Zhao, Y., & Li, S. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104642 · Cited by 162
Lawlor, P. A., Bland, R. J., Mouravlev, A., Young, D., & During, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.170 · Cited by 161
Self-citationNguyen, A. T., Mandard, S., Dray, C., Deckert, V., Valet, P., Besnard, P., Drucker, D. J., Lagrost, L., & Grober, J. (2014) · Diabetes · doi:10.2337/db13-0903 · Cited by 161
“To further investigate the role of the GLP-1/GLP-1R pathway in the LPS-mediated changes in glucose homeostasis, we assessed LPS action in GLP-1R-KO mice (19).”
MethodSelf-citationVal(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 160
A Pilot Study of Exenatide Actions in Alzheimer’s Disease
Mullins, R. J., Mustapic, M., Chia, C. W., Carlson, O., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 157
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O’Halloran, D., Hölscher, C., & O’Neill, C. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8199-5 · Cited by 168
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
“…in a wide array of roles ranging from the suppression of food intake, to effects on energy expenditure, to cardiovascular effects and neuroprotective actions (Barragan et al., 1999; During et al., 2003; Kanoski et al., 2016; Lee et al., 2018; Tang-Christensen et al., 1996; Turton et al., 1996).”
BackgroundGLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid
Gault, V. A., & Hölscher, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.025 · Cited by 168
Hölscher, C. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390891 · Cited by 170
Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes
Knudsen, L. B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030630m · Cited by 154
Diabetes drugs and neurological disorders: new views and therapeutic possibilities
Patrone, C., Eriksson, O., & Lindholm, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70125-6 · Cited by 161
Impact of Microbial Metabolites on Microbiota–Gut–Brain Axis in Inflammatory Bowel Disease
Banfi, D., Moro, E., Bosi, A., Bistoletti, M., Cerantola, S., Crema, F., Maggi, F., Giron, M. C., Giaroni, C., & Baj, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041623 · Cited by 171
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 159
Sharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Isacson, R., Nielsen, E. I., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O., & Wikström, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.008 · Cited by 161
Porter, D. W., Kerr, B. D., Flatt, P. R., Hölscher, C., & Gault, V. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01259.x · Cited by 159
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“GLP-1R agonism further inhibits gastric emptying (47); has cardio- and neuroprotective effects (48); lowers inflammation and apoptosis (49–53); stimulates b-cell proliferation in rodents (54); and exerts positive effects on learning, memory, and reward behavior (55, 56).”
BackgroundKosaraju, J., Murthy, V., Khatwal, R. B., Dubala, A., Chinni, S., Muthureddy Nataraj, S. K., & Basavan, D. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12148 · Cited by 146
Jensen, C. B., Pyke, C., Rasch, M. G., Dahl, A. B., Knudsen, L. B., & Secher, A. (2018) · Endocrinology · doi:10.1210/en.2017-00812 · Cited by 145
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Hölscher, C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15508 · Cited by 145
Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration
Banks, W. A., During, M. J., & Niehoff, M. L. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063222 · Cited by 155
Self-citationDuarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 162
Sun, J., Liu, S., Ling, Z., Wang, F., Ling, Y., Gong, T., Fang, N., Ye, S., Si, J., & Liu, J. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b07313 · Cited by 141
Gault, V. A., Lennox, R., & Flatt, P. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12432 · Cited by 141
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
“Albiglutide (formerly known as albugon) is a long-acting GLP-1R agonist, developed by GlaxoSmithKline through the genetic fusion of two repeats of human GLP-1(7-36) molecules to recombinant human albumin.”
BackgroundInfluentialLiu, J.-H., Yin, F., Guo, L.-X., Deng, X.-H., & Hu, Y.-H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2008.25 · Cited by 140
Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X., Wu, M., & Qi, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.009 · Cited by 149
The Promise of Neuroprotective Agents in Parkinson?s Disease
Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 156
A ketogenic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome
Benjamin, J. S., Pilarowski, G. O. W., Carosso, G. A., Zhang, L., Huso, D. L., Goff, L. A., Vernon, H. J., Hansen, K. D., & Bjornsson, H. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611431114 · Cited by 140
Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136
Sanz, C., Vázquez, P., Blázquez, C. P., Barrio, P. A., Álvarez, M., & Blázquez, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2009 · Cited by 140
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 153
Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition
Salameh, T. S., Bullock, K. M., Hujoel, I. A., Niehoff, M. L., Wolden-Hanson, T., Kim, J., Morley, J. E., Farr, S. A., & Banks, W. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150307 · Cited by 133
Self-citationRoux-en-Y gastric bypass surgery changes food reward in rats
Shin, A. C., Zheng, H., Pistell, P. J., & Berthoud, H.-R. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.174 · Cited by 133
Li, Y., Chigurupati, S., Holloway, H. W., Mughal, M. R., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 135
Darsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Kappe, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2012) · Clinical Science · doi:10.1042/cs20110374 · Cited by 130
Parthsarathy, V., & Hölscher, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058784 · Cited by 130
Qi, L., Ke, L., Liu, X., Liao, L., Ke, S., Liu, X., Wang, Y., Lin, X., Zhou, Y., Wu, L., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.052 · Cited by 136
GLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, C., Küçüker, M. U., Solaroğlu, I., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 126
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127
Hölscher, C. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.009 · Cited by 127
Lee, C., Jeon, S. J., Cho, K. S., Moon, E., Sapkota, A., Jun, H., Ryu, J. H., & Choi, J. W. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0550-2 · Cited by 136
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125
Shefer, G., Marcus, Y., & Stern, N. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.07.015 · Cited by 141
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing
Knauf, C., Cani, P. D., Kim, D.-H., Iglesias, M. A., Chabo, C., Waget, A., Colom, A., Rastrelli, S., Delzenne, N. M., Drucker, D. J., et al. (2008) · Diabetes · doi:10.2337/db07-1788 · Cited by 123
Self-citationObesity-associated biomarkers and executive function in children
Miller, A. L., Lee, H. J., & Lumeng, J. C. (2015) · Pediatric Research · doi:10.1038/pr.2014.158 · Cited by 122
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Belsham, D. D., Fick, L. J., Dalvi, P. S., Centeno, M.-L., Chalmers, J. A., Lee, P. K. P., Wang, Y., Drucker, D. J., & Koletar, M. M. (2009) · The FASEB Journal · doi:10.1096/fj.09-133454 · Cited by 120
Self-citationIncretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 153
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 119
Holst, J. J., & Deacon, C. F. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.005 · Cited by 129
Glucagon‐like peptide‐1 in the rat brain: Distribution of expression and functional implication
Gu, G., Roland, B., Tomaselli, K., Dolman, C. S., Lowe, C., & Heilig, J. S. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23282 · Cited by 119
Hyun Lee, C., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118
Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors
Edmondson, S. D., Wei, L., Xu, J., Shang, J., Xu, S. S., Pang, J., Chaudhary, A., Dean, D. C., He, H., Leiting, B., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.050 · Cited by 126
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Pérez–Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 126
Gilman, C. P., Perry, T., Furukawa, K., Grieg, N. H., Egan, J. M., & Mattson, M. P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02073.x · Cited by 125
Delivery of Galanin-Like Peptide to the Brain: Targeting with Intranasal Delivery and Cyclodextrins
Nonaka, N., Farr, S. A., Kageyama, H., Shioda, S., & Banks, W. A. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132381 · Cited by 114
Self-citationNutritional Status, Cognition, and Survival
Dagon, Y., Avraham, Y., Magen, I., Gertler, A., Ben-Hur, T., & Berry, E. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507607200 · Cited by 113
Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 112
Self-citationTherapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 110
Design and Application in Delivery System of Intranasal Antidepressants
Xu, J., Tao, J., & Wang, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.626882 · Cited by 126
Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS
Hanson, L. R., & Frey, W. H. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9039-x · Cited by 112
McIntyre, R. S., Powell, A. M., Kaidanovich-Beilin, O., Soczynska, J. K., Alsuwaidan, M., Woldeyohannes, H. O., Kim, A. S., & Gallaugher, L. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.021 · Cited by 110
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 109
Self-citationCai, H.-Y., Yang, J.-T., Wang, Z.-J., Zhang, J., Yang, W., Wu, M.-N., & Qi, J.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.114 · Cited by 108
Vadini, F., Simeone, P. G., Boccatonda, A., Guagnano, M. T., Liani, R., Tripaldi, R., Di Castelnuovo, A., Cipollone, F., Consoli, A., & Santilli, F. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0535-5 · Cited by 110
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
GLP-1 secretion by microglial cells and decreased CNS expression in obesity
Kappe, C., Tracy, L. M., Patrone, C., Iverfeldt, K., & Sjöholm, Å. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-276 · Cited by 107
“In GLP-1R knockout mice, neuronal injury is increased after kainate administration [2,10], and GLP-1 has been shown to protect the neuroblastoma cell line SH-SY5Y from amyloid-β-induced apoptosis [11].”
BackgroundGlucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential
Gromada, J., Brock, B., Schmitz, O., & Rorsman, P. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.t01-1-pto950502.x · Cited by 105
Briyal, S., Shah, S. Z., & Gulati, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.064 · Cited by 109
Cai, H.-Y., Hölscher, C., Yue, X.-H., Zhang, S., Wang, X.-H., Qiao, F., Yang, W., & Qi, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.022 · Cited by 107
Ma, T., Du, X., Pick, J. E., Sui, G., Brownlee, M., & Klann, E. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-12.2012 · Cited by 114
Multiple roles of short-chain fatty acids in Alzheimer disease
Chen, H., Meng, L., & Shen, L. (2022) · Nutrition · doi:10.1016/j.nut.2021.111499 · Cited by 103
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
Larsen, P. J., & Holst, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.026 · Cited by 125
Korol, S. V., Jin, Z., Babateen, O., & Birnir, B. (2015) · Diabetes · doi:10.2337/db14-0668 · Cited by 101
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialLi, Y., Bader, M., Tamargo, I., Rubovitch, V., Tweedie, D., Pick, C. G., & Greig, N. H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13169 · Cited by 103
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
Higgs, S., Spetter, M. S., Thomas, J. M., Rotshtein, P., Lee, M. D., Hallschmid, M., & Dourish, C. T. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117736917 · Cited by 129
Going with the grain: Fiber, cognition, and the microbiota-gut-brain-axis
Berding, K., Carbia, C., & Cryan, J. F. (2021) · Experimental Biology and Medicine · doi:10.1177/1535370221995785 · Cited by 100
PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation
Trapp, S., & Cork, S. C. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00333.2015 · Cited by 100
Heile, A., Wallrapp, C., Klinge, P. M., Samii, A., Kassem, M. S., Silverberg, G. D., & Brinker, T. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.07.071 · Cited by 103
Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99
Palleria, C., Leo, A., Andreozzi, F., Citraro, R., Iannone, M., Spiga, R., Sesti, G., Constanti, A., Sarro, G. D., Arturi, F., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.01.004 · Cited by 109
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer’s Disease: Review and Meta-Analysis
Athanasaki, A., Melanis, K., Tsantzali, I., Stefanou, M., Ntymenou, S., Paraskevas, S. G., Κalamatianos, T., Boutati, E. I., Lambadiari, V., Voumvourakis, K. I., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10040778 · Cited by 117
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96
Metadata
- Authors
- During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., & Haile, C. N.
- Affiliations
- University of Auckland (NZ)
- Thomas Jefferson University (US)
- St. Louis VA Medical Center (US)
- University of Toronto (CA)
- Corresponding author
- During, Matthew J
- ORCID
- Venue
- Nature Medicine
- Published
- 2003-08-17
- Volume
- 9
- Issue
- 9
- Pages
- 1173-1179
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2124852816
- Cited by
- 851
- References
- 42
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 50 · 2023: 39 · 2022: 58 · 2021: 53 · 2020: 44 · 2019: 36 · 2018: 37 · 2017: 39 · 2016: 34 · 2015: 54 · 2014: 46 · 2013: 47 · 2012: 43
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Marsden Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, associative learning, spatial learning, memory, hippocampus, neuroprotection, kainate-induced seizures, neuronal apoptosis, cognitive enhancement, gut-brain signaling
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Administration, Intranasal, Amino Acid Sequence, Animals, Behavior, Animal, Cognition, Glucagon, Hippocampus, Kainic Acid, Learning, Male, Molecular Sequence Data, Neurons, Peptide Fragments, Protein Precursors, Seizures, Signal Transduction, Gene Expression, Rats, Sprague-Dawley, Apoptosis, Sequence Homology, Amino Acid, Gene Transfer Techniques, Receptors, Glucagon, Mice, Knockout, Neuroprotective Agents, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.